Inventor · disambiguated record
Frank Herting
Also filed as: HERTING FRANK
13 granted patents·33 pending applications·102 citations·filing 2003–2023
89Inventor score
Top patents by PatentIndex Score
46 records- 0197US9695233B2Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseasesROCHE GLYCART AG·Filed 2013·Granted Jul 4, 2017·44 cites·11 claims
- 0291US10683345B2Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseasesROCHE GLYCART AG·Filed 2017·Granted Jun 16, 2020·5 cites·16 claims
- 0386US11525007B2Antibody fab and Fc variantsHOFFMANN LA ROCHE·Filed 2018·Granted Dec 13, 2022·3 cites·5 claims
- 0486US7098241B2Thiophene hydroxamic acid derivativesHOFFMANN LA ROCHE·Filed 2003·Granted Aug 29, 2006·27 cites·34 claims
- 0583US7208491B2N-monoacylated o-phenylenediaminesHOFFMANN LA ROCHE·Filed 2004·Granted Apr 24, 2007·19 cites·18 claims
- 0681US7396944B2Thiophene derivatives, their manufacture and use as pharmaceutical agentsHOFFMANN LA ROCHE·Filed 2005·Granted Jul 8, 2008·3 cites·19 claims
- 0780US2023212277A1Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseasesHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 0871US7423060B2Thiophene hydroxamic acid derivatives and their use as HDAC inhibitorsHOFFMANN LA ROCHE·Filed 2005·Granted Sep 9, 2008·1 cites·12 claims
- 0970US2015073129A1Combination therapy of antibodies against human CSF-1R and antibodies agains human PD-L1HOFFMANN LA ROCHE·Filed 2014·Application pending·0 cites
- 1069US2021095013A1Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseasesROCHE GLYCART AG·Filed 2020·Application pending·0 cites
- 1168US11512133B2Methods for treating colon cancer or inhibiting cell proliferation by administering a combination of antibodies against human CSF-1R and antibodies against human PD-L1HOFFMANN LA ROCHE·Filed 2020·Granted Nov 29, 2022·0 cites·14 claims
- 1267US2015071911A1COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH A mTOR INHIBITORROCHE GLYCART AG·Filed 2014·Application pending·0 cites
- 1364US2009246197A1Combination therapy of a type ii anti-cd20 antibody with increased antibody dependent cellular cytotoxicity (adcc)DUMONTET CHARLES·Filed 2009·Application pending·0 cites
- 1463US2024139192A1Methods and compositions comprising a braf inhibitor and a mek inhibitorHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 1563US2024197735A1Methods and compositions comprising a braf inhibitor and a pd-1 binding antagonistHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 1662US2015079073A1Combination therapy of an afucosylated cd20 antibody with fludarabine and/or mitoxantroneROCHE GLYCART AG·Filed 2014·Application pending·0 cites
- 1762US2016000911A1Combination therapy of a type ii anti-cd20 antibody with increased antibody dependent cellular cytotoxity (adcc)ROCHE GLYCART AG·Filed 2014·Application pending·0 cites
- 1862US2018346581A1Combination therapy of antibodies against human csf-1r and antibodies against human pd-l1HOFFMANN LA ROCHE·Filed 2018·Application pending·0 cites
- 1961US2016166688A9Combination therapy of an afucosylated cd20 antibody with bendamustineROCHE GLYCART AG·Filed 2014·Application pending·0 cites
- 2060US2014010804A1Combination therapy of an afucosylated cd20 antibody with fludarabine and/or mitoxantroneROCHE GLYCART AG·Filed 2013·Application pending·0 cites
- 2159US2014065134A1Combination therapy of a type ii anti-cd20 antibody with increased antibody dependent cellular cytotoxity (adcc)ROCHE GLYCART AG·Filed 2013·Application pending·0 cites
- 2258US2017051065A1Combination therapy of antibodies against human csf-1r and antibodies against human pd-l1HOFFMANN LA ROCHE·Filed 2016·Application pending·0 cites
- 2358US2014044705A1Combination therapy of an afucosylated cd20 antibody with bendamustineROCHE GLYCART AG·Filed 2013·Application pending·0 cites
- 2458US2012263713A1Combination therapy of an afucosylated CD20 antibody with fludarabine and/or mitoxantroneDREYLING MARTIN·Filed 2012·Application pending·0 cites
- 2557US2016017050A1Combination therapy of an afucosylated cd20 antibody with an anti-vegfROCHE GLYCART AG·Filed 2015·Application pending·0 cites
- 2657US2015265703A1COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH A mTOR INHIBITORROCHE GLYCART AG·Filed 2015·Application pending·0 cites
- 2756US2014322200A1Combination therapy of an afucosylated cd20 antibody with an anti-vegf antibodyROCHE GLYCART AG·Filed 2013·Application pending·0 cites
- 2855US7173060B2Oxime derivatives and their use as pharmaceutically active agentsHOFFMANN LA ROCHE·Filed 2004·Granted Feb 6, 2007·0 cites·12 claims
- 2955US2012301459A1Combination therapy of a type ii anti-cd20 antibody with increased antibody dependent cellular cytotoxicity (adcc)DUMONTET CHARLES·Filed 2011·Application pending·0 cites
- 3055US2011177067A1Combination therapy of a type ii anti-cd20 antibody with increased antibody dependent cellular cytotoxicity (adcc)HOFFMANN LA ROCHE·Filed 2011·Application pending·0 cites
- 3155US2012315268A1Combination therapy of an afucosylated cd20 antibody with bendamustineHERTING FRANK·Filed 2012·Application pending·0 cites
- 3254US7501451B2Mono-acylated o-phenylendiamines derivativesHOFFMANN LA ROCHE·Filed 2005·Granted Mar 10, 2009·0 cites·31 claims
- 3354US2013183290A1Combination therapy of an afucosylated cd20 antibody with an anti-vegf antibodyHERTING FRANK·Filed 2011·Application pending·0 cites
- 3454US2013280243A1COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH A mTOR INHIBITORROCHE GLYCART AG·Filed 2012·Application pending·0 cites
- 3554US2010267632A1Treatment of neurodegenerative disordersHASELBECK ANTON·Filed 2008·Application pending·0 cites
- 3654US2015274834A1Combination therapy of an afucosylated cd20 antibody with fludarabine and/or mitoxantroneROCHE GLYCART AG·Filed 2015·Application pending·0 cites
- 3754US2011165152A1Combination therapy of an afucosylated cd20 antibody with fludarabine and/or mitoxantroneDREYLING MARTIN·Filed 2010·Application pending·0 cites
- 3853US2010310581A1Combination therapy of a type ii anti-cd20 antibody with increased antibody dependent cellular cytotoxicity (adcc)HOFFMANN LA ROCHE·Filed 2010·Application pending·0 cites
- 3952US7071219B2Mono-acylated o-phenylendiamines derivativesHOFFMANN LA ROCHE·Filed 2004·Granted Jul 4, 2006·0 cites·39 claims
- 4052US2011165151A1Combination therapy of an afucosylated cd20 antibody with bendamustineHERTING FRANK·Filed 2010·Application pending·0 cites
- 4150US7638553B2Hydroxamates, their manufacture and use as pharmaceutical agentsHOFFMANN LA ROCHE·Filed 2005·Granted Dec 29, 2009·0 cites·20 claims
- 4246US7098247B2Arylene-carboxylic acid (2-amino-phenyl)-amide derivativesHOFFMANN LA ROCHE·Filed 2003·Granted Aug 29, 2006·0 cites·37 claims
- 4346US2007072795A1Treatment of neurodegenerative disordersHASELBECK ANTON·Filed 2005·Application pending·0 cites
- 4442US2018155431A1Combination therapy of antibody binding to angiopoietin 2 with antibody binding to programmed death ligand 1HOFFMANN LA ROCHE·Filed 2017·Application pending·0 cites
- 4540US2014140988A1Combination therapy of an afucosylated cd20 antibody with a mdm2 inhibitorROCHE GLYCART AG·Filed 2013·Application pending·0 cites
- 4632US2016347852A1Combination therapy of an anti-CD20 antibody with a Bcl-2 inhibitor and a MDM2 inhibitorHOFFMANN LA ROCHE·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Frank Herting files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →